Dexcom Further Advances Vision of Glucose Biosensing for All, shares under fresh Deutsche Bank coverage
23.06.2026 - 20:58:36 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:57.
Dexcom Inc. (US2521311074) sits in the spotlight on the NASDAQ today after Deutsche Bank initiated coverage with a Buy rating and a price target of 86 dollars for the diabetes technology group, according to an analyst note summarized by Investing.com. Deutsche Bank initiation report via Investing.com The stock trades around 69 dollars and is part of the S&P 500 health care cohort. StockTitan overview with latest DXCM price data
What Deutsche Bank highlights
In its initiation, Deutsche Bank points to Dexcom’s continuous glucose monitoring, or CGM, franchise as a central driver of medium term growth and applies a 2027 EV/EBITDA multiple of 16 times to derive the 86 dollar price target, as Investing.com reports. Deutsche Bank initiation report via Investing.com The analysts argue that after a volatile two years, marked by a second quarter 2024 drawdown, Dexcom shares could be positioned for a more consistent beat and raise cadence. Deutsche Bank initiation report via Investing.com
Deutsche Bank cites trailing twelve month revenue growth of roughly 16 percent and a gross margin of about 61.5 percent as evidence that Dexcom can support a premium valuation versus some medtech peers, according to the Investing.com summary. Deutsche Bank initiation report via Investing.com The firm also points to the role of newer sensors and expanded Type 2 diabetes indications in sustaining growth, positioning Dexcom alongside names such as Abbott in the CGM space. StockTitan overview with sector peer context
Other analyst views on Dexcom
Deutsche Bank’s move adds to a series of recent analyst updates on Dexcom shares, with Benchmark reiterating a Buy rating and a 77 dollar price target while projecting second quarter 2026 constant currency revenue of 1.281 billion dollars, a 10.7 percent increase year on year, according to Investing.com. Benchmark note on Dexcom via Investing.com The Benchmark report highlights the launch of a G7 15 day sensor as one factor that could support margin expansion in the medium term. Benchmark note on Dexcom via Investing.com
TD Cowen has raised its price target on Dexcom to 95 dollars while maintaining a Buy stance, citing data from the CONNECT and MACE clinical studies presented at the American Diabetes Association conference, and Mizuho has increased its target to 85 dollars after a randomized trial showed benefits of CGM for Type 2 diabetes patients compared with traditional blood glucose meter monitoring, according to the Investing.com analyst round-up. Analyst round-up covering TD Cowen and Mizuho via Investing.com These moves underscore a broadly constructive sell side view on Dexcom’s ability to grow in both the intensive insulin and non intensive treatment segments. Benchmark note on Dexcom via Investing.com
All news and data on the Dexcom shares
Further articles, prices and regulatory filings on Dexcom can be found in the dedicated topic section and on the company’s investor pages.
The business behind the stock
Dexcom generates its revenue primarily from the sale of continuous glucose monitoring systems such as the Dexcom G7, which comprise a wearable sensor, a transmitter and a receiver or smartphone app, and recently announced Dexcom Flex as a new CGM system aimed at adults with Type 2 diabetes not on intensive insulin therapy, with an initial launch in Germany, according to recent company communications compiled by StockTitan. Overview of Dexcom Flex launch via StockTitan In addition to hardware and software, Dexcom increasingly focuses on integrated data services and partnerships that embed CGM information into broader digital health platforms. StockTitan overview of Dexcom’s business activities
Where the Dexcom shares trade today
Dexcom shares (US2521311074) trade on NASDAQ at around 69.07 dollars as of June 22, 2026, according to price data cited by Investing.com. Latest DXCM price snapshot via Investing.com The listing reflects Dexcom’s position in the U.S. equity market as a specialized medtech name.
Dexcom shares at a glance
- Company: Dexcom Inc.
- ISIN: US2521311074
- WKN: A0D9T0
- Ticker: DXCM
- Trading venue: NASDAQ
- Price (as of 2026-06-22, 12:27): 69.07 USD
- Market cap: approximately 28.0 billion USD (as of 2026-06-22)
- Sector / industry: Health Care Equipment, Medical Devices
- Index membership: S&P 500
- Next earnings date: 2026-04-30
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a buy or sell recommendation, or a solicitation to trade any security. All data were obtained from sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research or consult a qualified advisor before making investment decisions.
